<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106897</url>
  </required_header>
  <id_info>
    <org_study_id>230LE101</org_study_id>
    <secondary_id>2013-005361-39</secondary_id>
    <nct_id>NCT02106897</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus</brief_title>
  <official_title>A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of Parts 1 and 2 is to evaluate the safety and tolerability of either
      single-ascending intravenous (IV) doses or a single subcutaneous (SC) dose of BIIB059 in
      healthy volunteers (HV), and a single IV dose in participants with Systemic Lupus
      Erythematosus (SLE). The primary objective of Part 3 is to evaluate the safety and
      tolerability of multiple SC doses of BIIB059 in healthy volunteers and in participants with
      SLE.

      Secondary objectives of Parts 1 and 2 are as follows: To estimate the PK parameters of
      single-ascending IV doses of BIIB059 in healthy volunteers and a single IV dose of BIIB059 in
      participants with SLE; To estimate the PK parameters and bioavailability (F) of a single SC
      dose of BIIB059 in healthy volunteers; To evaluate the immunogenicity of BIIB059 administered
      to healthy volunteers and participants with SLE. Secondary objectives of Part 3 are as
      follows: To estimate the PK parameters of multiple SC doses of BIIB059 in healthy volunteers
      and in participants with SLE; To evaluate the immunogenicity of BIIB059 administered SC to
      healthy volunteers and participants with SLE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 (single ascending dose in healthy volunteers) has closed to enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2014</start_date>
  <completion_date type="Actual">May 24, 2016</completion_date>
  <primary_completion_date type="Actual">May 24, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants that Experience Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Week 32</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUCinf) of BIIB059</measure>
    <time_frame>Up to Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of BIIB059</measure>
    <time_frame>Up to Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) of BIIB059</measure>
    <time_frame>Up to Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) of BIIB059</measure>
    <time_frame>Up to Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of BIIB059</measure>
    <time_frame>Up to Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of BIIB059</measure>
    <time_frame>Up to Week 32</time_frame>
    <description>For SC cohorts only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vss) of BIIB059</measure>
    <time_frame>Up to Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of BIIB059</measure>
    <time_frame>Up to Week 32</time_frame>
    <description>For SC cohorts only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioavailability (F) for a single SC dose of BIIB059</measure>
    <time_frame>Up to Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorption Rate Profile for a Single SC Dose of BIIB059</measure>
    <time_frame>Up to Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Develop Serum Anti-BIIB059 Antibodies</measure>
    <time_frame>Up to Week 32</time_frame>
  </secondary_outcome>
  <number_of_arms>19</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1, Cohort 1: BIIB059 0.05 mg/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 0.05 mg/kg IV dose, Once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 2: BIIB059 0.3 mg/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 0.3 mg/kg IV dose, Once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 3: BIIB059 1 mg/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 1 mg/kg IV dose, Once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 4: BIIB059 3 mg/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 3 mg/kg IV dose, Once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 5: BIIB059 10 mg/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 10 mg/kg IV dose, Once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 6: BIIB059 20 mg/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 20 mg/kg IV dose, Once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 7: BIIB059 50 mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 50 mg SC dose, Once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 1-6: Placebo IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo IV dose, Once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 7: Placebo SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo SC dose, Once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Cohort 8: BIIB059 20 mg/kg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 20 mg/kg IV dose, Once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Cohort 8: Placebo IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo IV dose, Once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3a, Cohort 9: BIIB059 20 mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 20 mg SC dose, Every 4 weeks for 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3a, Cohort 10: BIIB059 50 mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 50 mg SC dose, Every 4 weeks for 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3a, Cohort 11: BIIB059 150 mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 150 mg SC dose, Every 4 weeks for 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3a, Cohort 12: BIIB059 300 mg or less SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3a, Cohort 9-12: Placebo SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3b, Cohort 13: BIIB059 50 mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 50 mg SC dose, Every 4 weeks for 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3b, Cohort 14: BIIB059 300 mg or less SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3b, Cohort 13-14: Placebo SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB059</intervention_name>
    <description>See Arm Descriptions</description>
    <arm_group_label>Part 1, Cohort 1: BIIB059 0.05 mg/kg IV</arm_group_label>
    <arm_group_label>Part 1, Cohort 2: BIIB059 0.3 mg/kg IV</arm_group_label>
    <arm_group_label>Part 1, Cohort 3: BIIB059 1 mg/kg IV</arm_group_label>
    <arm_group_label>Part 1, Cohort 4: BIIB059 3 mg/kg IV</arm_group_label>
    <arm_group_label>Part 1, Cohort 5: BIIB059 10 mg/kg IV</arm_group_label>
    <arm_group_label>Part 1, Cohort 6: BIIB059 20 mg/kg IV</arm_group_label>
    <arm_group_label>Part 1, Cohort 7: BIIB059 50 mg SC</arm_group_label>
    <arm_group_label>Part 2, Cohort 8: BIIB059 20 mg/kg IV</arm_group_label>
    <arm_group_label>Part 3a, Cohort 9: BIIB059 20 mg SC</arm_group_label>
    <arm_group_label>Part 3a, Cohort 10: BIIB059 50 mg SC</arm_group_label>
    <arm_group_label>Part 3a, Cohort 11: BIIB059 150 mg SC</arm_group_label>
    <arm_group_label>Part 3a, Cohort 12: BIIB059 300 mg or less SC</arm_group_label>
    <arm_group_label>Part 3b, Cohort 13: BIIB059 50 mg SC</arm_group_label>
    <arm_group_label>Part 3b, Cohort 14: BIIB059 300 mg or less SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>See Arm Descriptions</description>
    <arm_group_label>Part 1, Cohort 1-6: Placebo IV</arm_group_label>
    <arm_group_label>Part 1, Cohort 7: Placebo SC</arm_group_label>
    <arm_group_label>Part 2, Cohort 8: Placebo IV</arm_group_label>
    <arm_group_label>Part 3a, Cohort 9-12: Placebo SC</arm_group_label>
    <arm_group_label>Part 3b, Cohort 13-14: Placebo SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part 1: Key Inclusion Criteria For Healthy Volunteers:

          -  Be in good health as determined by the Investigator, based on medical history,
             physical examination, and 12-lead ECG.

          -  Body mass index (BMI) between 18 and 30 kg/m2 and body weight ≥45 kg.

        Part 1: Key Exclusion Criteria For Healthy Volunteers:

          -  History of or positive test results at screening for the following: for human
             immunodeficiency virus (HIV), hepatitis C virus antibody (HCV Ab), hepatitis B virus
             (defined as positive for hepatitis B surface antigen [HBsAg] or hepatitis B core
             antibody [HBcAb]).

          -  - History of chronic, recurrent, or recent serious infection (e.g., pneumonia,
             septicemia) as determined by the Investigator within 3 months prior to screening and
             randomization.

          -  History of severe allergic or anaphylactic reactions or history of allergic reactions
             likely to be exacerbated by any component of the study drug.

          -  History of any clinically significant cardiovascular, endocrinologic, hematologic,
             hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic,
             psychiatric, renal, or other major disease, as determined by the Investigator.

          -  Any live or attenuated immunization/vaccination within 1 month prior to randomization
             or planned to occur during the study period.

          -  Blood donation (1 unit or more) within 1 month prior to randomization.

          -  Vigorous exercise (e.g., jogging, swimming laps, heavy gardening, hiking uphill, etc.)
             within 48 hours prior to Day -1

        Part II: Key Inclusion Criteria for SLE Participants:

          -  Definite SLE for at least 6 months duration or anti-dsDNA antibody, prior to
             screening.

          -  Presence of active lupus skin disease including acute, sub acute, and/or chronic
             cutaneous lupus (e.g., discoid) at the time of screening and randomization.

          -  BMI between 18 and &lt;40 kg/m2 and body weight ≥45 kg.

        Part II: Key Exclusion Criteria for SLE Participants:

          -  Active neuropsychiatric SLE including but not limited to the following: seizure, new
             or worsening impaired level of consciousness, psychosis, delirium or confusional
             state, aseptic meningitis, ascending or transverse myelitis, chorea, cerebellar
             ataxia, mononeuritis multiplex, or demyelinating syndromes.

          -  History of chronic, recurrent, or recent serious infection (e.g., pneumonia,
             septicemia) as determined by the Investigator within 3 months prior to screening and
             randomization.

          -  Symptoms of bacterial or viral infection (including upper respiratory tract infection)
             within 28 days prior to randomization.

          -  History of severe allergic or anaphylactic reactions or history of allergic reactions
             likely to be exacerbated by any component of the study drug.

          -  Evidence of skin conditions other than lupus skin disease (e.g., eczema) at screening
             or at the time of randomization that would interfere with evaluations of the effect of
             study treatment on lupus skin disease.

          -  Treatment with oral prednisone &gt;15 mg daily (or equivalent). Any prednisone regimen
             must be stable for at least 28 days before randomization and expected to remain stable
             for the duration of the study.

          -  Treatment with any antibiotics within 14 days prior to randomization.

        Part IIIa: Key Inclusion Criteria for Healthy Volunteers :

          -  Must be in good health as determined by the Investigator, based on medical history,
             physical examination, and 12-lead ECG.

          -  Must have a body mass index (BMI) between 18 and 30 kg/m2 and body weight ≥45 kg.

        Part IIIa: Key Exclusion Criteria for Healthy Volunteers:

          -  History of chronic, recurrent, or recent serious infection (e.g., pneumonia,
             septicemia) as determined by the Investigator within 3 months prior to screening and
             randomization

          -  History of severe allergic or anaphylactic reactions or history of allergic reactions
             likely to be exacerbated by any component of the study treatment.

          -  Treatment with any antibiotics within 14 days prior to randomization.

        Part IIIb: Key Inclusion Criteria for SLE Participants:

          -  Definite SLE for at least 6 months duration prior to screening

          -  Presence of active lupus skin disease including acute, subacute, and/or chronic
             cutaneous lupus (e.g., discoid), and/or hypocomplementemia , and/or positive
             anti-dsDNA antibody at the time of screening.

          -  Must have a BMI between 18 and &lt;40 kg/m2 and body weight ≥45 kg.

        Part IIIb: Key Exclusion Criteria for SLE Participants:

          -  Active neuropsychiatric SLE including but not limited to the following: seizure, new
             or worsening impaired level of consciousness, psychosis, delirium or confusional
             state, aseptic meningitis, ascending or transverse myelitis, chorea, cerebellar
             ataxia, mononeuritis multiplex, or demyelinating syndromes.

          -  History of chronic, recurrent, or recent serious infection (e.g., pneumonia,
             septicemia) as determined by the Investigator within 3 months prior to screening and
             randomization.

          -  History of severe allergic or anaphylactic reactions or history of allergic reactions
             likely to be exacerbated by any component of the study drug.

          -  Treatment with any antibiotics within 14 days prior to randomization.

        NOTE: Other protocol-defined inclusion/exclusion Criteria May Apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

